Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Phase I/II Study of the Safety and Efficacy of Perifosine and Bortezomib With or Without Dexamethasone for Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Bortezomib

NCT00401011 is registered in ClinicalTrials.gov with AEterna Zentaris as lead sponsor.

NCT NCT00401011
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00401011 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Phase I/II Study of the Safety and Efficacy of Perifosine and Bortezomib With or Without Dexamethasone for Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Bortezomib
Lead sponsor
AEterna Zentaris
Phase
Phase 1/2
Overall status
Completed
Start date
August 31, 2006
Completion date
July 31, 2011
Enrollment
84 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma, multiple myeloma in relapse